Hosted on MSN

Protagonist Therapeutics’ PN-881 Study: A Closer Look at Market Implications

Protagonist Therapeutics Inc ((PTGX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Yahoo Finance

Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg ...

HAMPTON, N.J., Nov. 05, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from the Company’s Phase 1b study of barzolvolimab in prurigo nodularis (PN).
MM&M

AstraZeneca and Ionis’ ATTRv-PN drug eplontersen shows promise in Phase III study

Ionis Pharmaceuticals and AstraZeneca unveiled promising Phase III results for the ATTR drug eplontersen, showing it met all of its co-primary endpoints and secondary endpoints compared to a placebo ...
Nasdaq

Protagonist (PTGX) Begins Dosing in Phase I Study With PN-235

Protagonist Therapeutics, Inc. PTGX announced that it has dosed the first patient in a phase I study, evaluating its oral interleukin-23 receptor (IL-23R) antagonist peptide – PN-235 (also known as ...
Business Wire

Mayo Clinic and PN Medical Publish Study that Shows How to Reduce Stress and Anxiety

An 18% reduction in stress was one of the most significant outcomes. ORLANDO, Fla.--(BUSINESS WIRE)--Mayo Clinic released the results of a clinical trial demonstrating the positive outcomes of a ...